Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2014 1
2015 1
2016 1
2017 1
2018 2
2019 1
2020 4
2021 4
2022 4
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura.
Völker LA, Kaufeld J, Balduin G, Merkel L, Kühne L, Eichenauer DA, Osterholt T, Hägele H, Kann M, Grundmann F, Kolbrink B, Schulte K, Gäckler A, Kribben A, Boss K, Potthoff SA, Rump LC, Schmidt T, Mühlfeld AS, Schulmann K, Hermann M, Gaedeke J, Sauerland K, Bramstedt J, Hinkel UP, Miesbach W, Bauer F, Westhoff TH, Bruck H, Buxhofer-Ausch V, Müller TJ, Wendt R, Harth A, Schreiber A, Seelow E, Tölle M, Gohlisch C, Bieringer M, Geuther G, Jabs WJ, Fischereder M, von Bergwelt-Baildon A, Schönermarck U, Knoebl P, Menne J, Brinkkoetter PT; German TTP-Study Group. Völker LA, et al. J Thromb Haemost. 2023 Mar;21(3):559-572. doi: 10.1016/j.jtha.2022.11.010. Epub 2022 Dec 22. J Thromb Haemost. 2023. PMID: 36696206 Free article.
Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia.
Eckardt JN, Stasik S, Röllig C, Petzold A, Sauer T, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Herbst R, Hänel M, Hanoun M, Kaiser U, Kaufmann M, Rácil Z, Mayer J, Oelschlägel U, Berdel WE, Ehninger G, Serve H, Müller-Tidow C, Platzbecker U, Baldus CD, Dahl A, Schetelig J, Bornhäuser M, Middeke JM, Thiede C. Eckardt JN, et al. Among authors: herbst r. Leukemia. 2023 Dec;37(12):2395-2403. doi: 10.1038/s41375-023-02061-1. Epub 2023 Oct 13. Leukemia. 2023. PMID: 37833543 Free PMC article.
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome.
Eckardt JN, Stasik S, Röllig C, Sauer T, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Herbst R, Hänel M, Hanoun M, Kaiser U, Kaufmann M, Rácil Z, Mayer J, Cerqueira T, Kroschinsky F, Berdel WE, Serve H, Müller-Tidow C, Platzbecker U, Baldus CD, Schetelig J, Siepmann T, Bornhäuser M, Middeke JM, Thiede C. Eckardt JN, et al. Among authors: herbst r. Blood Cancer J. 2023 Jan 24;13(1):18. doi: 10.1038/s41408-023-00790-1. Blood Cancer J. 2023. PMID: 36693840 Free PMC article.
Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations.
Eckardt JN, Stölzel F, Kunadt D, Röllig C, Stasik S, Wagenführ L, Jöhrens K, Kuithan F, Krämer A, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Herbst R, Hänel M, Hanoun M, Kaiser U, Kaufmann M, Rácil Z, Mayer J, Kroschinsky F, Berdel WE, Ehninger G, Serve H, Müller-Tidow C, Platzbecker U, Baldus CD, Schetelig J, Bornhäuser M, Thiede C, Middeke JM. Eckardt JN, et al. Among authors: herbst r. J Hematol Oncol. 2022 May 13;15(1):60. doi: 10.1186/s13045-022-01267-7. J Hematol Oncol. 2022. PMID: 35562747 Free PMC article.
Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.
Völker LA, Kaufeld J, Miesbach W, Brähler S, Reinhardt M, Kühne L, Mühlfeld A, Schreiber A, Gaedeke J, Tölle M, Jabs WJ, Özcan F, Markau S, Girndt M, Bauer F, Westhoff TH, Felten H, Hausberg M, Brand M, Gerth J, Bieringer M, Bommer M, Zschiedrich S, Schneider J, Elitok S, Gawlik A, Gäckler A, Kribben A, Schwenger V, Schoenermarck U, Roeder M, Radermacher J, Bramstedt J, Morgner A, Herbst R, Harth A, Potthoff SA, von Auer C, Wendt R, Christ H, Brinkkoetter PT, Menne J. Völker LA, et al. Among authors: herbst r. Blood Adv. 2020 Jul 14;4(13):3085-3092. doi: 10.1182/bloodadvances.2020001973. Blood Adv. 2020. PMID: 32634236 Free PMC article.
ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP.
Völker LA, Kaufeld J, Miesbach W, Brähler S, Reinhardt M, Kühne L, Mühlfeld A, Schreiber A, Gaedeke J, Tölle M, Jabs WJ, Özcan F, Markau S, Girndt M, Bauer F, Westhoff TH, Felten H, Hausberg M, Brand M, Gerth J, Bieringer M, Bommer M, Zschiedrich S, Schneider J, Elitok S, Gawlik A, Gäckler A, Kribben A, Schwenger V, Schoenermarck U, Roeder M, Radermacher J, Bramstedt J, Morgner A, Herbst R, Harth A, Potthoff SA, von Auer C, Wendt R, Christ H, Brinkkoetter PT, Menne J. Völker LA, et al. Among authors: herbst r. Blood Adv. 2020 Jul 14;4(13):3093-3101. doi: 10.1182/bloodadvances.2020001987. Blood Adv. 2020. PMID: 32634237 Free PMC article.
Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.
Kubasch AS, Giagounidis A, Metzgeroth G, Jonasova A, Herbst R, Diaz JMT, De Renzis B, Götze KS, Huetter-Kroenke ML, Gourin MP, Slama B, Dimicoli-Salazar S, Cony-Makhoul P, Laribi K, Park S, Jersemann K, Schipp D, Metzeler KH, Tiebel O, Sockel K, Gloaguen S, Mies A, Chermat F, Thiede C, Sapena R, Schlenk RF, Fenaux P, Platzbecker U, Adès L. Kubasch AS, et al. Among authors: herbst r. Leukemia. 2022 Oct;36(10):2519-2527. doi: 10.1038/s41375-022-01669-z. Epub 2022 Sep 7. Leukemia. 2022. PMID: 36071100 Free PMC article.
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial.
Röllig C, Serve H, Noppeney R, Hanoun M, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Müller-Tidow C, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Frickhofen N, Kullmer J, Kaiser U, Kiani A, Link H, Geer T, Reichle A, Junghanß C, Repp R, Meinhardt A, Dürk H, Klut IM, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Platzbecker U, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study Alliance Leukaemia (SAL). Röllig C, et al. Among authors: herbst r. Leukemia. 2021 Sep;35(9):2517-2525. doi: 10.1038/s41375-021-01148-x. Epub 2021 Feb 18. Leukemia. 2021. PMID: 33603142 Free PMC article. Clinical Trial.
Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.
Kürzel S, Blaudszun AR, Stahl L, Herbst R, Kroschinsky F, Birkmann J, Hänel A, Schaefer-Eckart K, Ehninger G, Fiedler F, Bornhäuser M, Fricke S, Hänel M. Kürzel S, et al. Among authors: herbst r. J Cancer Res Clin Oncol. 2022 May;148(5):1171-1181. doi: 10.1007/s00432-021-03702-7. Epub 2021 Jun 26. J Cancer Res Clin Oncol. 2022. PMID: 34176014 Clinical Trial.
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia.
Stasik S, Eckardt JN, Kramer M, Röllig C, Krämer A, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause S, Herbst R, Hänel M, Frickhofen N, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Rácil Z, Platzbecker U, Berdel WE, Mayer J, Serve H, Müller-Tidow C, Ehninger G, Bornhäuser M, Schetelig J, Middeke JM, Thiede C; Study Alliance Leukemia (SAL). Stasik S, et al. Among authors: herbst r. Blood Adv. 2021 Sep 14;5(17):3279-3289. doi: 10.1182/bloodadvances.2021004631. Blood Adv. 2021. PMID: 34459887 Free PMC article.
22 results